GlobeNewswire·Jul 15, 2026, 9:00 AM ET

NewcelX Granted Patent in Brazil for NCEL-101 in Type 1 Diabetes, Expanding Global IP Portfolio

NewcelX Ltd. (NASDAQ: NCEL) received Brazilian Patent Number BR 112018010946-0 from the Brazilian Patent and Trademark Office for its cell selection and enrichment technology.
The patent protects the manufacturing process for lead compound NCEL-101 until November 2036.
NCEL-101 is a stem-cell-derived therapy designed to restore functional insulin production for type 1 diabetes treatment.
The company recently held a successful FDA Type B Pre-IND meeting regarding NCEL-101 in combination with Eledon's tegoprubart, establishing a regulatory pathway for clinical trials.
Preclinical data for NCEL-101 shows approximately 60% beta cell co-expression of insulin and NKX6.1, MAFA expression for glucose-dependent insulin secretion, 99.98% endocrine lineage purity, and over 96% non-proliferative cells.
CEO Ronen Twito noted Brazil's large type 1 diabetes market, which includes approximately 500,000 patients growing at an annual rate of 4.4%.
The patent grant strengthens NewcelX's global intellectual property portfolio and enhances future partnering opportunities.
NewcelX is advancing a therapeutic approach integrating cell therapy, immune protection, and translational science using a validated human pluripotent stem cell platform.